In a different study, it was shown that, in response to combined gefitinib (EGFR inhibitor) and LPS treatment, mice expressing ectopic Fra-1 develop interstitial lung disease, accompanied by diminished levels of TNF-α, MIP-1α and MIP-2 when compared with wild-type mice [61]. This evidence concerns the gene CCL3 and interstitial lung disease.